Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients with High-Risk Prostate Cancer

Launched by HENRY FORD HEALTH SYSTEM · Jul 14, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to improve the number of Black patients with aggressive prostate cancer who get tested for genetic changes, which can help guide treatment options. The study involves a simple educational session where participants will learn about germline genetic testing—this is a type of test that checks for inherited genetic markers that could affect cancer risk. If they agree, they will then undergo the actual genetic testing through a commercial lab.

To be eligible for this study, participants need to be at least 18 years old, identify as Black or multiracial including Black, and have been diagnosed with prostate cancer that meets certain risk criteria. The trial aims to include men who are at higher risk due to family history or specific cancer characteristics. Those who have already had genetic testing or certain positive genetic tests will not be included. Participants can expect a supportive environment where they can learn about their options and help improve the understanding of genetic testing in their community.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Men, age greater than or equal to 18 years of age.
• • 2. Men who racially identify as black or multiracial including black
• • 3. Diagnosis of prostate cancer of any histology.
• • 4. Must meet NCCN guidelines for germline testing
• 1. Men with very low, low or intermediate risk prostate per NCCN guidelines with a positive family history or intraductal histology. Family history here is considered significant if the patient has:
• • a first degree relative with prostate cancer or more than one first/second degree relative with prostate cancer, or
• • ≥3 cancers on same side of family, especially diagnoses ≤50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, or urothelial cancer
• • 2. Men with high-risk, very-high risk (per NCCN definitions of risk groups), lymph node positive, or metastatic prostate cancer independent of family history of histology.
• Exclusion Criteria:
• • 1. Have had prior germline testing.
• • 2. Have somatic genetic testing that is positive for a possible germline variant.